CD5-positive marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) of the lung

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Terada, Tadashi ^a  

^a SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

Author keywords

Histopathology; Lung; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CD5 ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BIOPSY; CASE REPORT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LUNG TUMOR; LYMPHOID TISSUE; MARGINAL ZONE LYMPHOMA; PATHOLOGY; RESPIRATORY TRACT MUCOSA; TREATMENT OUTCOME;

AGED, 80 AND OVER; ANTIGENS, CD5; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOID TISSUE; LYMPHOMA, B-CELL, MARGINAL ZONE; RESPIRATORY MUCOSA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84858032063     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-16     Document Type: Article

References (20)

1. Nicolson AG, Harris NL. Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, pp88-90. IARC Press, Lyon, Travis WD, Brambilla E, Konrad Muller-Hermelink HK, Harris CC.
2. Isaacson PG, Chott A, Nakanuma S, Muller-Hermelink HK, Harris NL, Swerdlow SH. Extranodal marginal lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). World Health Organization Classification of tumour. Pathology and Genetics of tumors of haematopoietic and lymphoid system 2008, pp214-217. IARC Press, Lyon, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW.
3. Ballesteros E, Osborne BM, Matsushima AY. CD5+ low-grade marginal zone B-cell lymphomas with localized presentation. Am J Surg Pathol 1998, 22:201-207. 10.1097/00000478-199802000-00008, 9500221.
4. Tasaki K, Shichishima A, Furuta M, Yoshida S, Nakamura N, Abe M. CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hydridization and distinction between mantle cell lymphoma and MALT lymphoma. Pathol Int 2007, 57:101-107. 10.1111/j.1440-1827.2006.02063.x, 17300675.
5. Hisabe T, Imamura K, Fukukawa K, Tsuda S, Matsui T, Yao T, Kanda M, Oshima K, Kikuchi M. Regression of CD5-positive and Helicobactor-negative mucosa-associated lymphoid tissue lymphoma of the rectum after administration of antibiotics: report of a case. Dis Colon Rectum 2002, 45:1267-1270. 10.1007/s10350-004-6404-9, 12352248.
6. Sundeen JT, Longo DL, Jaffe ES. CD5 expression in B-cell small lymphocytic malignancies: correlations with clinical presentation and site of disease. Am J Surg Pathol 1992, 16:130-137. 10.1097/00000478-199202000-00005, 1370753.
7. Mikolaenko I, Listinsky CM. Systemic CD5+ MALT lymphoma: presentation with Waldenstrom syndrome. Ann Diagn Pathol 2009, 13:272-277. 10.1016/j.anndiagpath.2008.04.010, 19608087.
8. Ferry JA, Yang W, Zukerberg LR, Wotherspoon AC, Arnold A, Harris N. CD5+ extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for marrow involvement and relapse. Am J Clin Pathol 1996, 105:31-37.
9. Kubota T, Moritani T, Yoshino T, Nagai H, Terasaki H. Correlation of autoantibodies and CD5+ B cells in ocular adnexal marginal zone B-cell lymphomas. J Clin Pathol 2010, 63:79-82. 10.1136/jcp.2009.067603, 20026703.
10. Tsukamoto N, Kojima M, Uchiyama T, Takeuchi T, Karasawa M, Murakami H, Sato S. Primary cutaneous CD5+ marginal zone B-cell lymphoma resembling the plasm cell variant of Castleman's disease. APMIS 2007, 115:1426-1431. 10.1111/j.1600-0463.2007.00797.x, 18184415.
11. Wenzel C, Diekmann K, Fiebiger W, Mannhalter C, Chott A, Raderer M. CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour. Leukemia Lymphoma 2001, 42:823-829. 10.3109/10428190109099348, 11697516.
12. Batstone P, Forsyth L, Goodlad JR. Cytogenetic evidence for the origin of neoplastic cells in CD5-positive marginal zone B-cell lymphoma. Hum Pathol 2003, 34:1065-1067. 10.1053/S0046-8177(03)00400-3, 14608544.
13. Heuring AH, Franke F, Hutz W. Conjunctival CD5+ MALT lymphoma. Br J Ophthalmol 2001, 85:498-499. 1723925, 11302130.
14. Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. Pathol Int 2002, 52:740-746. 10.1046/j.1440-1827.2002.01416.x, 12685552.
15. Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med 2005, 206:271-275. 10.1620/tjem.206.271, 15942157.
16. Terada T. Ductal adenoma of the breast: Immunohistochemistry of two cases. Pathol Int 2008, 58:801-805. 10.1111/j.1440-1827.2008.02315.x, 19067857.
17. Swerdlow SH, Campo E, Seto M, Muller-Hermelink. Mantle cell lymphoma. World Health Organization Classification of tumour. Pathology and Genetics of tumors of haematopoietic and lymphoid system 2008, pp229-232. IARC Press, Lyon, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW.
18. Travis WD, Galvin JR. Non-neoplastic pulmonary lymphoid lesions. Thorax 2001, 56:964-971. 10.1136/thorax.56.12.964, 1745994, 11713361.
19. Kurtin PJ, Myers JL, Adlakha H, Strickler JG, Lohse C, Pankratz VS, Inwards DJ. Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type. Am J Surg Pathol 2001, 25:997-1008. 10.1097/00000478-200108000-00003, 11474283.
20. Borie R, Wilslez M, Thalbut G, et al. Clinical characteristics and prognostic factors of pulmonary MALT lymphoma. Eur Respir J 2009, 34:1408-1416. 10.1183/09031936.00039309, 19541720.